Affimed Therapeutics AG, of Heidelberg, Germany, said results from a phase I trial of AFM13, its monotherapy for the treatment of patients with advanced relapsing/refractory Hodgkin lymphoma, confirmed the drug's safety in 28 heavily pretreated patients.